June 8, 2016 9:04am

… Pre-open drops -$0.87 to $1.12

 


 

The primary endpoints were not met in FCSC’s P2 clinical trial of azficel-T for the treatment of vocal cord scarring resulting in chronic or severe dysphonia. Fibrocell intends to focus its efforts on the development of FCX-007 for the treatment of recessive dystrophic epidermolysis bullosa and its earlier stage programs.

 

The Bottom Line: Fibrocell intends to focus its efforts on the development of FCX-007 for the treatment of recessive dystrophic epidermolysis bullosa and its earlier stage programs.

FCSC closed at $2.06 and is DOWN -$0.87 or -43.72% to $1.12 in pre-market